Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
Gelteq (NASDAQ: GELS) has expanded its U.S. operations by appointing Adam Bendell as President of U.S. Operations. Bendell, who brings nearly a decade of experience in corporate strategy and retail operations, has previously worked with global brands including Deloitte Consulting, Calvin Klein, Tommy Hilfiger, and Cole Haan. The appointment aligns with Gelteq's growth strategy to scale operations in the U.S. market. The company specializes in developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, and pet care products.
Gelteq (NASDAQ: GELS) ha ampliato le sue operazioni negli Stati Uniti nominando Adam Bendell come Presidente delle Operazioni negli Stati Uniti. Bendell, che porta con sé quasi un decennio di esperienza nella strategia aziendale e nelle operazioni al dettaglio, ha precedentemente collaborato con marchi globali tra cui Deloitte Consulting, Calvin Klein, Tommy Hilfiger e Cole Haan. La nomina è in linea con la strategia di crescita di Gelteq per espandere le operazioni nel mercato statunitense. L'azienda si specializza nello sviluppo e nella commercializzazione di soluzioni di consegna a base di gel a marchio bianco per farmaci prescritti, nutraceutici e prodotti per animali domestici.
Gelteq (NASDAQ: GELS) ha ampliado sus operaciones en EE. UU. al nombrar a Adam Bendell como Presidente de Operaciones en EE. UU. Bendell, que aporta casi una década de experiencia en estrategia corporativa y operaciones minoristas, ha trabajado anteriormente con marcas globales como Deloitte Consulting, Calvin Klein, Tommy Hilfiger y Cole Haan. La nominación se alinea con la estrategia de crecimiento de Gelteq para escalar sus operaciones en el mercado estadounidense. La empresa se especializa en desarrollar y comercializar soluciones de entrega a base de gel de marca blanca para medicamentos recetados, nutracéuticos y productos para el cuidado de mascotas.
겔텍 (NASDAQ: GELS)은 아담 벤델을 미국 사업부의 사장으로 임명하여 미국 운영을 확장했습니다. 벤델은 기업 전략 및 소매 운영 분야에서 거의 10년의 경험을 갖고 있으며, 이전에 딜로이트 컨설팅, 캘빈 클라인, 톰미 힐피거, 콜 한과 같은 글로벌 브랜드와 함께 일한 경력이 있습니다. 이 임명은 겔텍의 미국 시장 운영 확장 전략과 일치합니다. 이 회사는 처방약, 영양 보조 식품 및 애완동물 관리 제품을 위한 화이트 라벨 젤 기반 배송 솔루션의 개발 및 상용화를 전문으로 하고 있습니다.
Gelteq (NASDAQ: GELS) a élargi ses opérations aux États-Unis en nommant Adam Bendell au poste de Président des opérations américaines. Bendell, qui apporte près d'une décennie d'expérience en stratégie d'entreprise et en opérations de vente au détail, a précédemment travaillé avec des marques mondiales telles que Deloitte Consulting, Calvin Klein, Tommy Hilfiger et Cole Haan. Cette nomination s'inscrit dans la stratégie de croissance de Gelteq pour développer ses opérations sur le marché américain. L'entreprise se spécialise dans le développement et la commercialisation de solutions de livraison à base de gel en marque blanche pour les médicaments sur ordonnance, les nutraceutiques et les produits de soin pour animaux de compagnie.
Gelteq (NASDAQ: GELS) hat seine Aktivitäten in den USA ausgeweitet, indem Adam Bendell zum Präsidenten der US-Operationen ernannt wurde. Bendell bringt fast ein Jahrzehnt Erfahrung in Unternehmensstrategie und Einzelhandelsbetrieb mit und hat zuvor mit globalen Marken wie Deloitte Consulting, Calvin Klein, Tommy Hilfiger und Cole Haan gearbeitet. Die Ernennung stimmt mit der Wachstumsstrategie von Gelteq überein, die Operationen im US-Markt auszubauen. Das Unternehmen ist auf die Entwicklung und Kommerzialisierung von weißen Label-Gel-basierten Lieferlösungen für verschreibungspflichtige Medikamente, Nahrungsergänzungsmittel und Tierpflegeprodukte spezialisiert.
- Strategic expansion into U.S. market with dedicated leadership
- Appointment of experienced executive with relevant industry background
- Enhanced focus on building distribution channels and market presence
- None.
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.
Gelteq Co-Founder and CEO Nathan Givoni stated, “The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of experience and insight into the domestic business landscape but also a deep commitment to our values and vision. We are confident that his leadership will enable us to connect more closely with our customers and partners, leading our expansion in this vital market as we look to build long-term value for all our stakeholders.”
Adam is an accomplished corporate strategist with nearly a decade of experience driving growth and transformational change for global companies, retail brands, and government organizations. He brings a deep understanding of the entire retail value chain, having worked on integrated brand, product, marketing, sales/distribution, and operations strategies for brands of various sizes from early-stage ventures to established global names including Deloitte Consulting, Calvin Klein, Tommy Hilfiger, and Cole Haan.
Bendell said, “I am honored and committed to fostering a culture of collaborative innovation as we look to gain increased traction in the U.S. market. Gelteq’s ingestible gel technology has the potential to revolutionize oral drug and nutrient delivery, and I look forward to leading our dedicated team as we educate consumers, build distribution channels, and position the Company for success.”
About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in the final prospectus filed on October 22, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
Contact:
CORE IR
516-222-2560
PR@gelteq.com
FAQ
Who is the new President of U.S. Operations for Gelteq (GELS)?
What is Gelteq's (GELS) main business focus?
What is Gelteq's (GELS) expansion strategy for 2024?
What is Adam Bendell's professional background before joining Gelteq (GELS)?
